 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2799;
P2
Assessment of exploratory biomarkers is also planned. A Safety Review Committee will conduct evaluations on an ongoing basis and two interim analyses will be performed.
- || IPH5201 / AstraZeneca, Innate
Trial initiation date: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov) - Jul 3, 2023
P2, N=70, Recruiting, Sponsor: Innate Pharma
A Safety Review Committee will conduct evaluations on an ongoing basis and two interim analyses will be performed. Initiation date: Feb 2023 --> Jun 2023
- |||| IPH5201 / AstraZeneca, Innate
New P2 trial: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov) - Feb 24, 2023
P2, N=70, Recruiting, Sponsor: Innate Pharma
- || IPH5201 / AstraZeneca, Innate, IPH5301 / Innate
$IPHA Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022 https://t.co/WOSFWBcn5I (Twitter) - Nov 30, 2022
- ||| IPH5201 / AstraZeneca, Innate
Monotherapy: $IPH $IPHA says anti-CD39 ( $AZN IPH5201) data in a poster at #ESMOIO22 (monotherapy & combo with durva) - cc @JacobPlieth (Twitter) - Nov 14, 2022
- | IPH5201 / AstraZeneca, Innate
ph2 data expected in 2024 for IPH5201 (Twitter) - Nov 2, 2022
- | SRF617 / Surface Oncology, TTX-030 / AbbVie, Trishula Therap, IPH5201 / AstraZeneca, Innate
$SURF "pausing" development of SRF617 (anti-CD39 MAb), relevant for Tizona $ABBV (TTX-030), $IPH $AZN (IPH5201) & $GILD $RCUS (AB598) (Twitter) - Nov 2, 2022
- Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_343;
P1
Conclusions IPH5201 was shown to block CD39 enzymatic activity, to lower Ado and increase ATP levels in the TME and finally to improve anti-tumor efficacy in preclinical models. Altogether, the expression profile of CD39 in early stage NSCLC and preclinical combination data support the clinical evaluation of IPH5201 in combination with D and CT in early stage NSCLC patients.
- Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
IPH5201 as Monotherapy or in Combination with Durvalumab (D) in Advanced Solid Tumours (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_341;
P1
Conclusions IPH5201 was well tolerated when used alone or in combination with D, with no new safety signals identified. PD were consistent with the mechanism of action.
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Trial completion, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Aug 15, 2022
P1, N=57, Completed, Sponsor: MedImmune LLC
PD were consistent with the mechanism of action. Active, not recruiting --> Completed
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - May 23, 2022
P1, N=57, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Trial completion date: Mar 2023 --> Jul 2022 | Trial primary completion date: Mar 2023 --> Jul 2022
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Enrollment closed, Enrollment change, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Nov 9, 2021
P1, N=57, Active, not recruiting, Sponsor: MedImmune LLC
Trial completion date: Mar 2023 --> Jul 2022 | Trial primary completion date: Mar 2023 --> Jul 2022 Recruiting --> Active, not recruiting | N=204 --> 57
- oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
[VIRTUAL] A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1872;
P1
Funding: AstraZeneca. Clinical trial identification: NCT04261075.
- | oxaliplatin / Generic mfg., IPH5201 / Innate, AstraZeneca, IPH5301 / Innate
Journal: Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. (Pubmed Central) - Jul 9, 2020
In a human CD39 knockin mouse preclinical model, IPH5201 increased the anti-tumor activity of the ATP-inducing chemotherapeutic drug oxaliplatin. These results support the use of anti-CD39 and anti-CD73 monoclonal antibodies and their combination with immune checkpoint inhibitors and chemotherapies in cancer.
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Enrollment open, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Apr 28, 2020
P1, N=204, Recruiting, Sponsor: MedImmune LLC
These results support the use of anti-CD39 and anti-CD73 monoclonal antibodies and their combination with immune checkpoint inhibitors and chemotherapies in cancer. Active, not recruiting --> Recruiting
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Enrollment closed, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Apr 23, 2020
P1, N=204, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
Enrollment open, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Mar 12, 2020
P1, N=204, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca, IPH5201 / AstraZeneca, Innate
New P1 trial, Combination therapy, Monotherapy, Metastases: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Feb 6, 2020
P1, N=204, Not yet recruiting, Sponsor: MedImmune LLC